Related Experiment Videos
Sumatriptan: pharmacological basis and clinical results
1Gothenburg Migraine Clinic, Gothenburg, Sweden. carl.dahlof@migraineclinic.se
Current Medical Research and Opinion
|December 5, 2002
Summary
Sumatriptan, a selective serotonin (5-HT)1B/1D agonist, effectively treats migraine attacks across various formulations. All triptans demonstrate similar efficacy and safety profiles in clinical practice.
Area of Science:
- Neurology
- Pharmacology
Background:
- Sumatriptan is the first selective serotonin (5-HT)1B/1D agonist developed for acute migraine treatment.
- Available in oral, subcutaneous, nasal spray, and suppository forms.
Purpose of the Study:
- To evaluate the efficacy of sumatriptan in various formulations for acute migraine treatment.
- To compare sumatriptan's effectiveness against placebo for migraine symptoms.
Main Methods:
- Placebo-controlled clinical trials.
- Administration of sumatriptan via subcutaneous, oral, intranasal, and rectal routes.
Main Results:
- Sumatriptan significantly outperformed placebo in relieving migraine headache and associated symptoms like nausea, photophobia, and phonophobia.
- Rapid relief options include sumatriptan injection (10-minute onset), suitable for severe attacks or vomiting.
- Nasal spray and suppositories offer alternatives for patients experiencing nausea or preferring non-oral/non-injection methods.
Conclusions:
- Sumatriptan is a highly effective treatment for acute migraine attacks, with various formulations catering to different patient needs.
- Post-market, all triptans, including newer agents like zolmitriptan, rizatriptan, and naratriptan, show comparable efficacy, tolerability, and safety after dose adjustments.